Skip to main content
Top
Published in: Acta Diabetologica 9/2019

01-09-2019 | Insulins | Original Article

Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer

Authors: Valentina Pasquale, Erica Dugnani, Daniela Liberati, Paolo Marra, Antonio Citro, Tamara Canu, Martina Policardi, Libera Valla, Antonio Esposito, Lorenzo Piemonti

Published in: Acta Diabetologica | Issue 9/2019

Login to get access

Abstract

Aim

More than 40% of pancreatic ductal adenocarcinoma (PDAC) patients have glucose intolerance or diabetes. The association has led to two hypotheses: PDAC causes diabetes or diabetes shares risk factors for the development of PDAC. In order to elucidate the relationship between diabetes and PDAC, we investigated the glucose metabolism during tumorigenesis in the LSL-KrasG12D/+; LSL-Trp53R172H/+; and Pdx-1-Cre (KPC) mouse, a genetically engineered model of PDAC.

Methods

Male and female KPCs have been fed with standard diet (SD) or high-fat diet (HFD). The imaging-based 4-class tumor staging was used to follow pancreatic cancer development. Not fasting glycemia, 4-h fasting glycemia, insulin, C-peptide, glucose tolerance after OGTT and abdominal fat volume were measured during tumorigenesis.

Results

PDAC development did not lead to an overt diabetic phenotype or to any alterations in glucose tolerance in KPC fed with SD. Consumption of HFD induced higher body weight/abdominal fat volume and worsened glucose homeostasis both in control CRE mice and only in early tumorigenesis stages of the KPC mice, excluding that the cancer development itself acts as a trigger for the onset of dysmetabolic features.

Conclusion

Our data demonstrate that carcinogenesis in KPC mice is not associated with paraneoplastic diabetes.
Appendix
Available only for authorised users
Literature
1.
3.
go back to reference Lucas AL et al (2016) Global trends in pancreatic cancer mortality from 1980 through 2013 and predictions for 2017. Clin Gastroenterol Hepatol 14(10):1452–1462 e4CrossRef Lucas AL et al (2016) Global trends in pancreatic cancer mortality from 1980 through 2013 and predictions for 2017. Clin Gastroenterol Hepatol 14(10):1452–1462 e4CrossRef
4.
go back to reference Wei M et al (2017) The need for differentiating diabetes-specific mortality from total mortality when comparing metformin with insulin regarding cancer survival. Acta Diabetol 54(2):219–220CrossRef Wei M et al (2017) The need for differentiating diabetes-specific mortality from total mortality when comparing metformin with insulin regarding cancer survival. Acta Diabetol 54(2):219–220CrossRef
5.
go back to reference Yang WS et al (2017) Association between type 2 diabetes and cancer incidence in Taiwan: data from a prospective community-based cohort study. Acta Diabetol 54(5):455–461CrossRef Yang WS et al (2017) Association between type 2 diabetes and cancer incidence in Taiwan: data from a prospective community-based cohort study. Acta Diabetol 54(5):455–461CrossRef
6.
go back to reference Balzano G et al (2014) Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. Acta Diabetol 51(5):801–811CrossRef Balzano G et al (2014) Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. Acta Diabetol 51(5):801–811CrossRef
7.
go back to reference Dugnani E et al (2016) Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: results of a prospective observational study in surgical patients. Pancreatology 16(5):844–852CrossRef Dugnani E et al (2016) Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: results of a prospective observational study in surgical patients. Pancreatology 16(5):844–852CrossRef
8.
go back to reference Pannala R et al (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134(4):981–987CrossRef Pannala R et al (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134(4):981–987CrossRef
9.
go back to reference Sah RP et al (2013) New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10(7):423–433CrossRef Sah RP et al (2013) New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10(7):423–433CrossRef
10.
go back to reference Chari ST et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129(2):504–511CrossRef Chari ST et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129(2):504–511CrossRef
11.
go back to reference Aggarwal G et al (2012) Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology. 143(6):1510–1517 e1CrossRef Aggarwal G et al (2012) Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology. 143(6):1510–1517 e1CrossRef
12.
go back to reference Basso D et al (2006) Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta 372(1–2):120–128CrossRef Basso D et al (2006) Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta 372(1–2):120–128CrossRef
13.
go back to reference Basso D et al (2011) Altered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: relevance of the S100A8 N-terminal peptide (NT-S100A8). J Cell Physiol 226(2):456–468CrossRef Basso D et al (2011) Altered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: relevance of the S100A8 N-terminal peptide (NT-S100A8). J Cell Physiol 226(2):456–468CrossRef
14.
go back to reference Kang M et al (2016) VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Cancer Lett 373(2):241–250CrossRef Kang M et al (2016) VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Cancer Lett 373(2):241–250CrossRef
15.
go back to reference Hingorani SR et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469–483CrossRef Hingorani SR et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469–483CrossRef
16.
go back to reference Dugnani E et al (2018) Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Carcinogenesis 39(9):1197–1206CrossRef Dugnani E et al (2018) Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Carcinogenesis 39(9):1197–1206CrossRef
17.
go back to reference Garg SK et al (2014) Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 16(2):97–110CrossRef Garg SK et al (2014) Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 16(2):97–110CrossRef
18.
go back to reference McAuliffe MJ et al (2001) Medical image processing, analysis and visualization in clinical research. In: Proceedings 14th IEEE symposium on computer-based medical systems. CBMS 2001 McAuliffe MJ et al (2001) Medical image processing, analysis and visualization in clinical research. In: Proceedings 14th IEEE symposium on computer-based medical systems. CBMS 2001
19.
go back to reference van Dijk TH et al (2013) A novel approach to monitor glucose metabolism using stable isotopically labelled glucose in longitudinal studies in mice. Lab Anim 47(2):79–88CrossRef van Dijk TH et al (2013) A novel approach to monitor glucose metabolism using stable isotopically labelled glucose in longitudinal studies in mice. Lab Anim 47(2):79–88CrossRef
20.
go back to reference Ben Q et al (2011) The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 47(2):248–254CrossRef Ben Q et al (2011) The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer 47(2):248–254CrossRef
21.
go back to reference Li D et al (2011) Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 22(2):189–197CrossRef Li D et al (2011) Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 22(2):189–197CrossRef
22.
go back to reference Chari ST et al (2008) Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134(1):95–101CrossRef Chari ST et al (2008) Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134(1):95–101CrossRef
23.
go back to reference Danai LV et al (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558(7711):600–604CrossRef Danai LV et al (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558(7711):600–604CrossRef
24.
go back to reference Lee JW et al (2016) Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr Protoc Pharmacol 73:14 39 1–14 39 20CrossRef Lee JW et al (2016) Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr Protoc Pharmacol 73:14 39 1–14 39 20CrossRef
25.
go back to reference Parks BW et al (2015) Genetic architecture of insulin resistance in the mouse. Cell Metab 21(2):334–346CrossRef Parks BW et al (2015) Genetic architecture of insulin resistance in the mouse. Cell Metab 21(2):334–346CrossRef
26.
go back to reference Zechner D et al (2015) Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Cell Biosci 5:51CrossRef Zechner D et al (2015) Characterization of novel carcinoma cell lines for the analysis of therapeutical strategies fighting pancreatic cancer. Cell Biosci 5:51CrossRef
27.
go back to reference Khasawneh J et al (2009) Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A 106(9):3354–3359CrossRef Khasawneh J et al (2009) Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A 106(9):3354–3359CrossRef
28.
go back to reference Cheon EC et al (2011) Alteration of strain background and a high omega-6 fat diet induces earlier onset of pancreatic neoplasia in EL-Kras transgenic mice. Int J Cancer 128(12):2783–2792CrossRef Cheon EC et al (2011) Alteration of strain background and a high omega-6 fat diet induces earlier onset of pancreatic neoplasia in EL-Kras transgenic mice. Int J Cancer 128(12):2783–2792CrossRef
29.
go back to reference Dawson DW et al (2013) High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) 6(10):1064–1073CrossRef Dawson DW et al (2013) High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) 6(10):1064–1073CrossRef
30.
go back to reference Philip B et al (2013) A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 145(6):1449–1458CrossRef Philip B et al (2013) A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 145(6):1449–1458CrossRef
31.
go back to reference McDevitt TM, Tisdale MJ (1992) Tumour-associated hypoglycaemia in a murine cachexia model. Br J Cancer 66(5):815–820CrossRef McDevitt TM, Tisdale MJ (1992) Tumour-associated hypoglycaemia in a murine cachexia model. Br J Cancer 66(5):815–820CrossRef
32.
go back to reference Liang C et al (2016) Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai) 48(11):969–979CrossRef Liang C et al (2016) Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai) 48(11):969–979CrossRef
33.
go back to reference Basturk O et al (2011) GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas 40(2):187–192CrossRef Basturk O et al (2011) GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas 40(2):187–192CrossRef
34.
go back to reference Yu M et al (2015) Metabolic phenotypes in pancreatic cancer. PLoS ONE 10(2):e0115153CrossRef Yu M et al (2015) Metabolic phenotypes in pancreatic cancer. PLoS ONE 10(2):e0115153CrossRef
35.
go back to reference Geng Y et al (2015) Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol 41(11):1508–1514CrossRef Geng Y et al (2015) Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol 41(11):1508–1514CrossRef
36.
go back to reference Balzano G et al (2017) A preoperative score to predict early death after pancreatic cancer resection. Digest Liver Dis 49(9):1050–1056CrossRef Balzano G et al (2017) A preoperative score to predict early death after pancreatic cancer resection. Digest Liver Dis 49(9):1050–1056CrossRef
37.
go back to reference Kimura Y, Kikuyama M, Kodama Y (2015) Acute pancreatitis as a possible indicator of pancreatic cancer: the importance of mass detection. Intern Med 54(17):2109–2114CrossRef Kimura Y, Kikuyama M, Kodama Y (2015) Acute pancreatitis as a possible indicator of pancreatic cancer: the importance of mass detection. Intern Med 54(17):2109–2114CrossRef
38.
go back to reference Bracci PM et al (2009) Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control 20(9):1723–1731CrossRef Bracci PM et al (2009) Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control 20(9):1723–1731CrossRef
39.
go back to reference Chan YC, Leung PS (2007) Acute pancreatitis: animal models and recent advances in basic research. Pancreas 34(1):1–14CrossRef Chan YC, Leung PS (2007) Acute pancreatitis: animal models and recent advances in basic research. Pancreas 34(1):1–14CrossRef
Metadata
Title
Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer
Authors
Valentina Pasquale
Erica Dugnani
Daniela Liberati
Paolo Marra
Antonio Citro
Tamara Canu
Martina Policardi
Libera Valla
Antonio Esposito
Lorenzo Piemonti
Publication date
01-09-2019
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 9/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01335-4

Other articles of this Issue 9/2019

Acta Diabetologica 9/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.